Evaluation of Postpartum Glucose Tolerance Test Results Based on Criteria and Timing: Implications for Diagnostic Accuracy and Clinical Practice

Highlights

• Inpatient postpartum glucose testing in women with gestational diabetes mellitus (GDM) markedly improves OGTT completion rates compared to outpatient testing.
• The 2022 ADA diagnostic criteria, requiring two abnormal OGTT values for diabetes diagnosis, significantly reclassify previously defined diabetes cases as glucose intolerance compared to ACOG criteria.
• Timing of postpartum testing critically influences diagnostic yield: testing on postpartum day 1 shows higher rates of glucose intolerance and diabetes compared to day 2 or later tests.
• Current variability in diagnostic criteria and test timing stresses the urgent need for standardized national guidelines on postpartum glucose screening protocols.

Background

Gestational diabetes mellitus (GDM) predisposes women to an increased risk of developing type 2 diabetes mellitus (T2DM) postpartum. Postpartum glucose tolerance testing, typically via the 75-g, 2-hour oral glucose tolerance test (OGTT), is the gold standard for early detection of dysglycemia, enabling timely intervention. However, postpartum screening rates remain suboptimal due to logistical challenges and patient noncompliance, particularly with outpatient testing mandates. Furthermore, diagnostic criteria for postpartum diabetes have evolved, notably with the 2022 American Diabetes Association (ADA) revision demanding two abnormal OGTT values to confirm diabetes, differing from criteria endorsed by the American College of Obstetricians and Gynecologists (ACOG), which previously accepted a single abnormal value. These shifts potentially affect patient classification and consequent management.

Additionally, the timing of testing postpartum may affect glucose metabolism due to physiological and hormonal changes shortly after delivery. This review explores evidence regarding the impact of diagnostic criteria and test timing on postpartum OGTT interpretation and classification in women with GDM, synthesizing findings from the recent cohort study by Bastian et al. (2026) alongside existing literature.

Key Content

Chronological Development of Postpartum Diabetes Diagnostic Criteria

Postpartum diabetes screening has traditionally followed criteria aligned with the general adult population, where a single abnormal OGTT value sufficed for diagnosis. The 2022 ADA guidelines introduced a more stringent diagnostic threshold requiring abnormalities on two OGTT measurements to affirm diabetes, aiming to reduce false positives and better stratify risk.

Prior meta-analyses have demonstrated that reliance on a single abnormal value may overestimate diabetes prevalence postpartum, potentially leading to overtreatment. Bastian et al.’s (2026) retrospective cohort study applied both ACOG and revised ADA criteria to the same postpartum OGTT data, revealing significant reclassification: most women labeled diabetic by ACOG criteria shifted to glucose intolerance under ADA rules (Bowker χ 2 =24, P < .001). These findings corroborate prior observational studies indicating that ADA criteria enhance diagnostic specificity without compromising sensitivity significantly.

Impact of Testing Setting on Postpartum OGTT Completion and Outcomes

Historically, outpatient postpartum glucose tolerance testing suffers from low completion rates, with multiple factors such as childcare responsibilities, transportation, and health system navigation affecting adherence. Bastian et al. compared two cohorts: a traditional outpatient-only approach (2023) and a hybrid model (2024-2025) offering inpatient screening during delivery hospitalization or outpatient testing.

Completion rates in the hybrid cohort (73.9%) were substantially greater than in the traditional group (31.7%, P < .001). Inpatient testing was associated with significantly higher detection rates of glucose intolerance (48.0%) and overt diabetes (15.4%). This aligns with prior observational studies suggesting that inpatient testing increases screening uptake and may capture postpartum hyperglycemia more sensitively, possibly due to temporal metabolic changes or reduced missed appointments.

However, the inpatient testing environment may transiently influence glucose metabolism related to stress, recovery, and altered dietary intake, which must be considered when interpreting results.

Effect of Timing of Postpartum OGTT on Diagnostic Classification

Physiological insulin resistance and beta-cell function fluctuate dynamically postpartum. Testing very early (e.g., postpartum day 1) may reflect acute metabolic perturbations due to peripartum stress, inflammation, and hormonal fluxes (e.g., cortisol, prolactin).

In Bastian et al.’s study, testing on postpartum day 1 correlated with increased odds of glucose intolerance (aOR 2.20; 95% CI 1.36–3.57) and overt diabetes (aOR 3.92; 95% CI 1.69–9.06) relative to outpatient testing beyond day 2. Testing from day 2 onwards did not show significant associations, suggesting postpartum day 1 testing may overestimate dysglycemia prevalence.

These data complement earlier reports indicating that standard timing for postpartum OGTT is optimal at 4–12 weeks postpartum, as recommended by both ADA and ACOG guidelines, to stabilize hormonal and metabolic changes for accurate assessment. Nonetheless, inpatient testing before discharge remains attractive for its logistical advantages, but results warrant cautious interpretation.

Integration of Diagnostic Criteria, Testing Setting, and Timing: Clinical Implications

Clinical practice requires balancing diagnostic accuracy with patient adherence and pragmatic feasibility. The 2022 ADA criteria improve specificity, potentially reducing unnecessary labeling and interventions. Inpatient testing markedly improves screening rates and may capture early dysglycemia but risks overdiagnosis if conducted too early (postpartum day 1).

Clinicians should interpret inpatient OGTT results with awareness of revised criteria and consider confirmatory outpatient testing for abnormal findings on day 1 to mitigate false positives. Tailored patient counseling and system-level interventions to maximize outpatient test completion remain essential.

Expert Commentary

The retrospective cohort by Bastian et al. (2026) represents a methodologically robust analysis contextualizing a pressing clinical challenge: enhancing postpartum diabetes detection while reducing misclassification. Their dual-cohort design illuminates real-world changes in practice and underscores how evolving diagnostic thresholds reshape epidemiological estimates and clinical decisions.

The substantial improvement in screening completion through inpatient testing aligns with broader literature advocating for integrated care pathways that capitalize on hospitalization to mitigate patient attrition. Yet, this convenience must be tempered by the physiological context of early postpartum testing, which may transiently elevate glucose levels, leading to possible overdiagnosis.

The ADA’s shift toward requiring two abnormal OGTT values strikes a critical balance between sensitivity and specificity but complicates comparisons with legacy data and necessitates clinician education.

Limitations of the Bastian et al. study include single-center design and potential selection bias in hybrid cohort testing modality choice. Future multicenter prospective studies should evaluate the long-term prognostic implications of different testing timings and criteria-based classifications for postpartum glucose dysregulation, including outcomes like progression to overt T2DM and cardiovascular risk.

Conclusion

Optimal postpartum diabetes screening in women with GDM hinges on coordinated strategies encompassing diagnostic criteria selection, testing timing, and setting. Inpatient OGTT enhances test completion but must be interpreted cautiously, especially when conducted on postpartum day 1, due to transient metabolic alterations. The revised 2022 ADA criteria refine diagnostic accuracy, reclassifying many cases previously diagnosed as diabetes to glucose intolerance, reducing false positives.

National consensus guidelines are urgently needed to harmonize postpartum glucose testing algorithms, including recommendations on timing relative to delivery and test interpretation frameworks. In clinical practice, a hybrid approach leveraging inpatient screening to maximize adherence, coupled with confirmatory outpatient testing and application of current ADA criteria, may optimize early detection and management of postpartum dysglycemia, ultimately improving long-term maternal metabolic health.

References

1. Bastian IN, Gandhi M, Turrentine MA. Evaluation of Postpartum Glucose Tolerance Test Results Based on Criteria and Timing. Obstet Gynecol. 2026 Mar 26;148(1):4-10. PMID: 41886750.
2. American Diabetes Association. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2022. Diabetes Care. 2022;45(Suppl 1):S17–S38.
3. American College of Obstetricians and Gynecologists. Practice Bulletin No. 190: Gestational Diabetes Mellitus. Obstet Gynecol. 2018;131(2):e49–e64.
4. Tol J, et al. Postpartum screening after gestational diabetes mellitus: effects on detection of prediabetes and diabetes. J Clin Endocrinol Metab. 2019;104(12):6227–34.
5. Kim C, Newton KM, Knopp RH. Gestational diabetes and the incidence of type 2 diabetes: a systematic review. Diabetes Care. 2002;25(10):1862-8.